Progression and direction of humanized antibody research.
- Author:
Yun LIN
1
;
Xi-Yun YAN
Author Information
1. Center of Molecular Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijng 100101, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies;
therapeutic use;
Antibodies, Monoclonal;
therapeutic use;
Humans;
Mice;
Protein Engineering
- From:
Chinese Journal of Biotechnology
2004;20(1):1-5
- CountryChina
- Language:Chinese
-
Abstract:
After its advent, monoclonal antibody has gone an uneven way to its present wide applications in clinical practices, during which the humanized antibody set an important milestone accompanying a series of technique renovations, such as PCR technique, phage display and transgenic animals. Humanized antibody has developed from chimeric antibody and reshaped antibody to the present fully human antibody. Humanization of murine antibodies has been the future direction of therapeutic antibodies and this can be reflected from the fact that humanized antibodies or even human antibodies have made up majority of the therapeutic antibodies both in clinical test and in the market. The present techniques have enabled the production of fully human antibodies and given chances to the arising of antibody derivatives. They not only overcome the deficiency in application of murine antibody with different strategies, but also provide more weapons for human therapeutics. However, modifications of monoclonal antibody aiming at clinical applications need more research work in the mechanisms of antibody effector system, as well as comprehensive understanding in regulation of human immune system.
